Article
SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG.
The Journal of clinical investigation - 2 Jan 2018
Shoag Jonathan, Liu Deli, Blattner Mirjam, Sboner Andrea, Park Kyung, Deonarine Lesa, Robinson Brian D, Mosquera Juan Miguel, Chen Yu, Rubin Mark A, Barbieri Christopher E
Abstract excerpt
Nearly 50% of prostate cancers harbor gene fusions that lead to overexpression of the transcription factor ERG, while a mutually exclusive 10% of prostate cancers harbor recurrent mutations in the gene encoding the E3 ubiquitin ligase SPOP. Recent reports suggest that SPOP acts as a ubiquitin ligase for ERG and propose that ERG stabilization is the oncogenic effector of SPOP mutation. Here, we used human prostate...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.